TY  - JOUR
AU  - Fuentes-Fayos, Antonio C
AU  - Perez-Gomez, Jesus M
AU  - G-Garcia, Miguel E
AU  - Jimenez-Vacas, Juan M
AU  - Blanco-Acevedo, Cristobal
AU  - Sanchez-Sanchez, Rafael
AU  - Solivera, Juan
AU  - Breunig, Joshua J
AU  - Gahete, Manuel D
AU  - Castaño, Justo P
AU  - Luque, Raul M
PY  - 2022
DO  - 10.1186/s13046-022-02241-4
UR  - http://hdl.handle.net/10668/20348
T2  - Journal of experimental & clinical cancer research : CR
AB  - Glioblastoma is one of the most devastating cancer worldwide based on its locally aggressive behavior and because it cannot be cured by current therapies. Defects in alternative splicing process are frequent in cancer. Recently, we demonstrated that...
LA  - en
PB  - BioMed Central
KW  - Antitumor therapy
KW  - BCL2L1 splicing variants
KW  - Glioblastoma
KW  - Glioma mouse models
KW  - Splicing factor SF3B1
KW  - Animals
KW  - Apoptosis
KW  - Cell line, tumor
KW  - Cell proliferation
KW  - Disease models, animal
KW  - Glioblastoma
KW  - Humans
KW  - Mice
KW  - Phosphoproteins
KW  - RNA splicing factors
KW  - Survival analysis
KW  - TOR serine-threonine kinases
KW  - Transfection
KW  - Xenograft model antitumor assays
KW  - Bcl-X protein
KW  - Beta catenin
TI  - SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
TY  - research article
VL  - 41
ER  -